The Medical Xchange

  • Edit profile
  • Logout
Login    Register

Expert Review


Sexual Health 2017

Chapter 1: Hypoactive Sexual Desire Disorder

Dr. Marla Shapiro C.M.
Professor , Family and Community Medicine
University of Toronto, Ontario

Atlanta – Hypoactive Sexual Desire Disorder (HSDD) is a condition that is estimated to affect 7% to 10% of the global population of women. Recently, there has been an evolution in thought with respect to the definition of HSDD and its classification and nomenclature. Recent revisions distinguish HSDD from other disorders of female sexual dysfunction such as female genital arousal disorder (FGAD).

Show review

Chapter 2: Treatments – Psychology

Lori A. Brotto PhD, R Psych
Professor, Faculty of Medicine | Department of Obstetrics & Gynaecology
Executive Director, Women's Health Research Institute | Canada Research Chair in Women's Sexual Health
The University of British Columbia, Vancouver, British Columbia

Atlanta – Hypoactive Sexual Desire Disorder is a condition that is estimated to affect 10% of adult women.1 Psychological treatments like cognitive behavioral therapy and mindfulness can be employed to treat these women. Clinicians need to recognize cultural or religious factors that influence the patient, as well as mental health conditions that may need to be addressed in women who present with reduced sexual desire.

Show review

Chapter 3: Treatments – Pharmacology

James G. Pfaus, PhD, IF
Professor, Department of Psychology
Researcher, Center for Studies in Behavioral Neurobiology (CSBN)
Concordia University, Montréal, Québec, Canada

Atlanta – Hypoactive sexual desire disorder (HSDD) is estimated to affect about one in every 10 adult women1 . Several promising pharmacotherapies for HSDD are currently in clinical trials as adjuncts to traditional sex therapy. These include hormonal treatments and agents that target the central nervous system (CNS) to increase sexual excitation or decrease sexual inhibition in specific centers of the brain that are crucial for sexual desire. These novel pharmacological agents are new tools in a more comprehensive and patient-oriented approach to the treatment of HSDD.

Show review


The information and opinions expressed herein are those of the participants and do not necessarily reflect those of Xfacto Communications Inc. or the sponsor. The distribution of this meeting report was made possible through industry support under written agreement that ensures editorial independence. The content is for educational purposes and should not be taken as an endorsement of any products, uses or doses. Physicians should consult the appropriate monograph before prescribing any drugs. Distribution, reproduction, alteration of this program is strictly prohibited without written consent of Xfacto Communications Inc. Copyright 2020. All rights reserved. The Medical XchangeTM

This web site is solely for healthcare professionals

Yes, I am a healthcare professional No, I am not a healthcare professional
New user?
Sign up for the Medical Xchange Here you'll find expert commentary from the most recent medical meetings around the world, as well as features and interviews with top healthcare professionals.
First name* Last name*
Title Gender*
Email* Confirm Email*
Password* Password must have at least 8 characters with at least one Capital letter, one lower case letter and one number or special character Confirm Password*
Profession* Speciality*
Country* Province*